Delivery of exogenous miR-19b by Wharton’s Jelly Mesenchymal Stem Cells attenuates transplanted kidney ischemia/reperfusion injury by regulating cellular metabolism
Drug Delivery and Translational Research · 2025-03 · 15 (3) · 925-938
DOI: 10.1007/s13346-024-01645-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 25.06.2024. Verfasst von Xiaoqiang Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital, Zhengzhou University People'…. Hauptthemen laut MEDLINE: MicroRNAs, Reperfusion Injury, Mesenchymal Stem Cells, Kidney Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Key Scientific Research Projects in Universities of Henan Province, Henan Province Medical Science and Technology Research Project.
Abstract (Originalsprache)
Renal ischemia-reperfusion injury (IRI) frequently occurs following kidney transplantation, and exosomes derived from umbilical cord mesenchymal stem cells (WJ-MSC-Exos) have shown promise in treating IRI in transplanted kidneys. Our study delved into the potential mechanism of WJ-MSC-Exos in ameliorating IRI in transplanted kidneys, revealing that miR-19b is abundantly present in WJ-MSC-Exos. Both in vivo and in vitro experiments demonstrated that the absence of miR-19b abolished the protective effects of WJ-MSC-Exos against renal IRI. Mechanistically, miR-19b suppressed glycogen synthase kinase-3β (GSK3β) expression, thereby stabilizing PDXK protein through direct binding. Treatment with WJ-MSC-Exos led to reduced PDXK levels and enhanced pyridoxine accumulation, ultimately mitigating IRI in transplanted kidneys and I/R-induced HK2 cell apoptosis. These findings elucidate the underlying mechanism of WJ-MSC-Exos in alleviating IRI in transplanted kidneys, unveiling novel therapeutic targets for post-kidney transplantation IRI and providing a solid theoretical foundation for the clinical application of WJ-MSC-Exos in IRI treatment post-transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, China.
- Department of Nephrology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, China.
- Department of Urology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, No. 7 Weiwu Road, Zhengzhou, 450003, China. ytz460@hotmail…
Förderung
- Key Scientific Research Projects in Universities of Henan Province
- Henan Province Medical Science and Technology Research Project
Zitieren
APA
Wu, X., Wu, X., Wang, Z., Tian, X., Zhang, C., Cao, G., Gu, Y., & Yan, T. (2025). Delivery of exogenous miR-19b by Wharton’s Jelly Mesenchymal Stem Cells attenuates transplanted kidney ischemia/reperfusion injury by regulating cellular metabolism. Drug Delivery and Translational Research, 15(3), 925-938. https://doi.org/10.1007/s13346-024-01645-3
Vancouver
Wu X, Wu X, Wang Z, Tian X, Zhang C, Cao G, et al. Delivery of exogenous miR-19b by Wharton’s Jelly Mesenchymal Stem Cells attenuates transplanted kidney ischemia/reperfusion injury by regulating cellular metabolism. Drug Delivery and Translational Research. 2025;15(3):925-938. doi:10.1007/s13346-024-01645-3
BibTeX
@article{Wu2025,
author = {Wu, Xiaoqiang and Wu, Xuan and Wang, Zhiwei and Tian, Xiangyong and Zhang, Chan and Cao, Guanghui and Gu, Yue and Yan, Tianzhong},
title = {Delivery of exogenous miR-19b by Wharton’s Jelly Mesenchymal Stem Cells attenuates transplanted kidney ischemia/reperfusion injury by regulating cellular metabolism},
journal = {Drug Delivery and Translational Research},
year = {2025},
volume = {15},
number = {3},
pages = {925--938},
doi = {10.1007/s13346-024-01645-3}
}
EUVIMED